DACT3-AS1: A Potential Drug Target and Biomarker (G100506068)

Target Name: DACT3-AS1

NCBI ID: G100506068

DACT3-AS1

Other Name(s): DACT3 antisense RNA 1 | DACT3 antisense RNA 1, transcript variant 1

DACT3-AS1: A Potential Drug Target and Biomarker

DACT3-AS1, also known as DACT3-AS1-22, is a protein that is expressed in human tissues and has been identified as a potential drug target and biomarker. The protein is encoded by the gene DACT3-AS1 and has been shown to play a role in a variety of cellular processes, including cell adhesion, migration, and invasion.

DACT3-AS1: Structure and Function

The DACT3-AS1 protein is a member of the actinin family and is composed of 214 amino acid residues. It has a molecular weight of 21.9 kDa and a calculated pI of 2.8. DACT3-AS1 is expressed in a variety of human tissues, including lung, heart, liver, and pancreas, and has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DACT3-AS1 has been shown to play a role in several cellular processes, including:

1. Cell Adhesion and Migration: DACT3-AS1 has been shown to be involved in cell adhesion and migration. It has been shown to interact with several cell adhesion molecules, including E-cadherin, N-cadherin, and vimentin. These interactions may help to regulate the movement of cells along the body's surface and contribute to the development of cancer.
2. invasion and metastasis: DACT3-AS1 has been shown to be involved in the invasion and metastasis of cancer cells. It has been shown to promote the migration of cancer cells along the bloodstream and contribute to the development of new tumors in other organs.
3. Cell Communication: DACT3-AS1 has been shown to be involved in cell communication. It has been shown to interact with several intracellular signaling pathways, including the TGF-β pathway. These interactions may help to regulate the exchange of information between cells and contribute to the development of neurodegenerative diseases.

DACT3-AS1 as a Drug Target

DACT3-AS1 has been identified as a potential drug target due to its involvement in several cellular processes that are associated with the development of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One potential approach to targeting DACT3-AS1 is to use small molecules that can modulate its activity. For example, inhibitors of the TGF-β pathway, which is known to be involved in the development of cancer, could be used to reduce the activity of DACT3-AS1 and inhibit its contribution to these diseases.

Another potential approach to targeting DACT3-AS1 is to use antibodies that can selectively bind to it and inhibit its activity. This approach could be useful for studying the role of DACT3-AS1 in specific diseases and for identifying new treatments.

DACT3-AS1 as a Biomarker

DACT3-AS1 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

For example, DACT3-AS1 has been shown to be elevated in the bloodstream in patients with pancreatic cancer, a common and often deadly form of cancer. This suggests that DACT3-AS1 may be a useful biomarker for the early detection of pancreatic cancer.

DACT3-AS1 has also been shown to be elevated in the bloodstream in patients with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that DACT3-AS1 may be a useful biomarker for the early detection of these diseases.

DACT3-AS1 has also been shown to be elevated in the bloodstream in patients with autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. This suggests that DACT3-AS1 may be a useful biomarker for the early detection of these disorders.

Conclusion

DACT3-AS1 is a protein that has been shown to play a role in several cellular processes that are associated with the development of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target and biomarker, DACT3-AS1 is a promising target for the development of new treatments for these diseases. Further research is needed to fully understand the role of DACT3-AS1 in these diseases and to develop effective treatments.

Protein Name: DACT3 Antisense RNA 1

The "DACT3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DACT3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets